Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study

被引：0
作者：
Campiotti, Leonardo [1 ]
Suter, Matteo B. [2 ]
Dentali, Francesco [1 ]
机构：
[1] Univ Insubria, Dept Med & Surg, Varese, Italy
[2] Azienda Socio Sanit Terr Sette Laghi, Med Oncol, Varese, Italy
来源：
CANCER | 2021年 / 127卷 / 06期
关键词：
IMATINIB; DASATINIB; NILOTINIB;
D O I：
10.1002/cncr.33282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：978 / 978
页数：1
相关论文
共 6 条
[1]   Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study [J].
Cayssials, Emilie ;
Torregrosa-Diaz, Jose ;
Gallego-Hernanz, Pilar ;
Tartarin, Florence ;
Systchenko, Thomas ;
Maillard, Natacha ;
Desmier, Deborah ;
Machet, Antoine ;
Fleck, Emmanuel ;
Corby, Anne ;
Motard, Carine ;
Denis, Guillaume ;
Herbelin, Andre ;
Gombert, Jean-Marc ;
Roy, Lydia ;
Ragot, Stephanie ;
Leleu, Xavier ;
Guilhot, Francois ;
Chomel, Jean-Claude .
CANCER, 2020, 126 (15) :3438-3447
[2]   Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response [J].
Cervantes, Francisco ;
Correa, Juan-Gonzalo ;
Perez, Isabel ;
Garcia-Gutierrez, Valentin ;
Redondo, Sara ;
Colomer, Dolors ;
Jimenez-Velasco, Antonio ;
Steegmann, Juan-Luis ;
Sanchez-Guijo, Fermin ;
Ferrer-Marin, Francisca ;
Pereira, Arturo ;
Osorio, Santiago .
ANNALS OF HEMATOLOGY, 2017, 96 (01) :81-85
[3]   De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial [J].
Clark, Richard E. ;
Polydoros, Fotios ;
Apperley, Jane F. ;
Milojkovic, Dragana ;
Rothwell, Katherine ;
Pocock, Christopher ;
Byrne, Jennifer ;
de lavallade, Hugues ;
Osborne, Wendy ;
Robinson, Lisa ;
O'Brien, Stephen G. ;
Read, Lucy ;
Foroni, Letizia ;
Copland, Mhairi .
LANCET HAEMATOLOGY, 2019, 6 (07) :E375-E383
[4]   Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data [J].
Fassoni, Artur C. ;
Baldow, Christoph ;
Roeder, Ingo ;
Glauche, Ingmar .
HAEMATOLOGICA, 2018, 103 (11) :1825-1834
[5]   Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis [J].
Garcia-Ferrer, Manuel ;
Wojnicz, Aneta ;
Mejia, Gina ;
Koller, Dora ;
Zubiaur, Pablo ;
Abad-Santos, Francisco .
CLINICAL THERAPEUTICS, 2019, 41 (12) :2558-2570
[6]   Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia [J].
Miura, Masatomo .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (05) :645-654
1